|1.||Harmatz, Paul: 3 articles (08/2014 - 08/2009)|
|2.||Turbeville, Sean: 3 articles (01/2010 - 01/2009)|
|3.||Guffon, Nathalie: 2 articles (08/2014 - 03/2014)|
|4.||Decker, Celeste: 2 articles (03/2014 - 03/2008)|
|5.||Wraith, J E: 2 articles (03/2013 - 12/2008)|
|6.||Nicely, Helen: 2 articles (08/2009 - 01/2009)|
|7.||Foehr, Erik: 2 articles (09/2008 - 06/2008)|
|8.||White, Joleen T: 2 articles (09/2008 - 06/2008)|
|9.||Van Tuyl, Andrea: 2 articles (09/2008 - 06/2008)|
|10.||Boyer, Ryan: 2 articles (09/2008 - 06/2008)|
|1.||Spinal Cord Compression
05/01/2013 - "The prescribed dosage of 1mg/kg IV weekly with galsulfase ERT is shown to be safe and effective in slowing and/or improving certain aspects of the disease, although patients should be closely monitored for complications associated with the natural history of the disease, especially cardiac valve involvement and spinal cord compression. "
08/01/2009 - "Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy."
08/01/2009 - "This is the first case report of reversed papilledema and improved visual acuity in an 11-year-old MPS VI patient receiving galsulfase (Naglazyme), an enzyme-replacement therapy (ERT) of recombinant human arylsulfatase B (rhASB) (Harmatz et al., J Pediatr 148(4), 533-539, 2006)."
|3.||Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy)
08/01/2014 - "Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study."
03/01/2014 - "Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI."
01/01/2009 - "A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase."
03/01/2013 - "Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy."
09/01/2010 - "Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures."
01/01/2013 - "Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase."
12/01/2008 - "In this report we demonstrate the safety of home treatment with Elaprase for mucopolysaccharidosis type II (17 patients) and Naglazyme for mucopolysaccharidosis type VI (6 patients). "
12/01/2008 - "Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively."
12/01/2010 - "Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation."
09/01/2008 - "Most patients receiving Naglazyme (galsulfase, rhASB) enzyme replacement therapy for mucopolysaccharidosis type VI develop an antibody response. "
|5.||Mucopolysaccharidosis II (Hunter Syndrome)
12/01/2011 - "Enzyme replacement therapy (ERT) is now available for MPS I (Hurler, Hurler-Scheie and Scheie syndromes) (laronidase), MPS II (Hunter syndrome) (idursulfase) and MPS VI Maroteaux-Lamy (galsulfase), and is in development for MPS IV (Morquio syndrome) and MPS VII (Sly syndrome). "
12/01/2010 - "Mucopolysaccharidosis (MPS) type I (Hurler and Scheie diseases), II (Hunter syndrome) and VI (Maroteaux-Lamy disease) also benefit from ERT using laronidase (Aldurazyme(®)), idursulfase (Elaprase(®)) and galsulfase (Naglazyme(®)), respectively. "
|2.||N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B)
|4.||Immunoglobulin G (IgG)
|5.||Immunoglobulin E (IgE)
|8.||human GAA protein (Myozyme)
|1.||Enzyme Replacement Therapy
|2.||Hematopoietic Stem Cell Transplantation